News|Articles|November 17, 2026

Giredestrant Approval: What Nurses Need to Know and What Comes Next

Author(s)Alex Biese
Fact checked by: By ONN Staff

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

The FDA approval of giredestrant (Wilserdly) plus everolimus (Afinitor) gives patients with ESR1-mutated, estrogen receptor (ER)–positive, HER2-negative advanced breast cancer an all-oral option after progression on endocrine-based therapy, and it places new testing, monitoring, and education responsibilities on oncology nurses, according to Erica L. Mayer, MD, MPH, principal investigator of the phase 3 evERA Breast Cancer trial.

Related to this article